Sell 3/26/2025Upgraded
AEON Biopharma, Inc. (AEON) was upgraded to D from E+ on 3/26/2025 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 133.74% from -$6.17M to $2.08M, earnings per share increased from -$11.52 to $3.4676, and operating cash flow increased 78.98% from -$2.96M to -$621.

Sell 10/25/2024Downgrade
AEON Biopharma, Inc. (AEON) was downgraded to E+ from D on 10/25/2024 due to a significant decline in the valuation index, efficiency index and growth index.

Sell 8/16/2024Upgraded
AEON Biopharma, Inc. (AEON) was upgraded to D from E+ on 8/16/2024 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 239.06% from -$118.02M to $164.11M, earnings per share increased from -$3.1667 to $4.2249, and total capital increased 93.13% from -$193.09M to -$13.26M.

Sell 6/5/2024Downgrade
AEON Biopharma, Inc. (AEON) was downgraded to E+ from D- on 6/5/2024 due to a large decline in the solvency index, volatility index and efficiency index. Net income declined 349.71% from -$26.24M to -$118.02M, the quick ratio declined from 0.4 to 0.1, and total capital declined 26.4% from -$152.77M to -$193.09M.

Sell 6/3/2024Upgraded
AEON Biopharma, Inc. (AEON) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index.

Sell 5/15/2024Downgrade
AEON Biopharma, Inc. (AEON) was downgraded to E+ from D- on 5/15/2024 due to a large decline in the valuation index and growth index. Earnings per share declined from $0.3748 to -$0.7062.

Sell 1/24/2024Upgraded
AEON Biopharma, Inc. (AEON) was upgraded to D- from E+ on 1/24/2024 due to a major increase in the solvency index and valuation index. The quick ratio increased from 0.03 to 1.14.

Sell 8/23/2023None
AEON Biopharma, Inc. (AEON) was downgraded to E+ from U on 08/23/2023.